Compare KRNT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | GOSS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.1M | 796.2M |
| IPO Year | 2015 | 2019 |
| Metric | KRNT | GOSS |
|---|---|---|
| Price | $13.86 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $19.75 | $8.83 |
| AVG Volume (30 Days) | 290.8K | ★ 4.7M |
| Earning Date | 02-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,041,000.00 | $44,051,000.00 |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | $2.57 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $11.93 | $0.76 |
| 52 Week High | $31.24 | $3.87 |
| Indicator | KRNT | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 47.95 |
| Support Level | $13.64 | $2.38 |
| Resistance Level | $14.65 | $3.00 |
| Average True Range (ATR) | 0.51 | 0.22 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 9.73 | 66.26 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.